Ken Takanashi - Jun 3, 2022 Form 4/A - Amendment Insider Report for Satsuma Pharmaceuticals, Inc. (STSA)

Role
Director
Signature
/s/ Thomas P. O'Neil as Attorney-in-Fact for Ken Takanashi
Stock symbol
STSA
Transactions as of
Jun 3, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/9/2022, 03:11 PM
Date Of Original Report
Jun 7, 2022
Previous filing
Aug 18, 2021
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding STSA Common Stock, $0.0001 par value 2.79M Jun 3, 2022 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STSA Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jun 3, 2022 Common Stock 30K $3.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
F2 The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting.

Remarks:

Amendment made to correct number of beneficially owned shares reported in Table I